Participate in an Alzheimer’s Research Study
If you or someone you love is experiencing memory loss, or has been diagnosed with Alzheimer’s disease, perhaps you should consider participating in a clinical research study. Participants receive a high standard of care, and research shows that people involved in clinical trials tend to do somewhat better than people in a similar stage of their disease who are not enrolled in clinical trials.*
Perhaps the best reason to participate in an Alzheimer’s clinical trial is so that you can take an active role in your health care, by educating yourself regarding your condition. You will obtain access to top quality medical care from our Board Certified physicians at a medical research healthcare facility specializing in Alzheimer’s care.
Health insurance is not necessary to participate. Patients who qualify for our clinical trials will receive all study related care and treatment at no cost. In some cases you may be compensated for your time and travel. You may even gain access to research treatments before they are widely available.
Without volunteers for clinical trials, improved treatments, including a cure for Alzheimer’s disease can never become a reality.
Premiere Research Institute is currently seeking volunteers for the A4 Study.
If you are a healthy older adult with normal memory, this could be the right time for you to join the fight to prevent the memory loss associated with Alzheimer’s disease.
What is the A4 study?
The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (the “A4 study “for short) is a clinical study for older individuals (65 to 85 years of age) who may be at risk for the memory loss associated with Alzheimer’s disease (AD).
The A4 study is investigating a new drug intervention that may reduce the impact of a protein known as “amyloid” or “beta amyloid” forming plaques in the brain. Scientists believe that accumulation of amyloid in the brain may play a key role in the eventual development of AD-related memory loss. The A4 anti-amyloid investigational drug targets amyloid build-up in the brain with the aim of slowing memory loss associated with the development of AD.
Am I eligible?
The A4 study will enroll 1,000 people between the ages of 65 through 85 with normal thinking and memory function but with evidence of amyloid plaque buildup in the brain. Physicians and researchers will use PET amyloid imaging scans to determine whether a potential participant has evidence of elevated amyloid buildup. Individuals with elevated amyloid on the PET scan will be eligible to become participants in the A4 clinical study. People who do not show evidence of elevated brain amyloid may be asked to participate in a separate study. This group will not receive the study drug but will complete the same memory tests every six months to compare changes in cognition over time.
* Source: alz.org (official website for the Alzheimer’s Association)
Interested in learning more about A4? Contact Premiere Institute of Palm Beach by calling (561) 296-3850 or fill out the form below.
Articles about Alzheimer’s Disease
To read one of our most recent articles about Alzheimer’s Disease just click the title of the article.
The FDA has recently approved the first blood test that indicates the presence of bleeding in the brain from mild traumatic brain injury (TBI). This new test is intended to identify certain patients who do not need imaging to determine whether they have intracranial...read more
Cognitive training exercises may be effective at improving or delaying age-related cognitive decline, according to a report from the National Academies of Science, Engineering, and Medicine (NASEM). The report examined a systematic review of randomized controlled...read more
A blood test that screens for the presence and buildup of amyloid plaques in the brain decades before the onset of Alzheimer’s symptoms could be a promising and widely accessible way to detect Alzheimer’s disease early. Studies have indicated that the pathology of...read more
Carl Sadowsky, M.D., FAAN Benefits of Controlling Blood Pressure Controlled blood pressure is advantageous to our overall health and longevity. In addition to providing benefits to our cardiovascular system, optimal blood pressure management also improves...read more
Untreated Hearing Loss May Accelerate Cognitive Decline and Dementia Evidence suggests that age-related hearing loss, particularly in those over the age of 65, can lead to cognitive decline and dementia if left untreated. Impairments in communication and psychosocial...read more
What is The MIND Diet? The MIND diet is based on the Mediterranean and DASH (Dietary Approach to Systolic Hypertension) diets, with an emphasis on natural plant-based foods and limited consumption of saturated fats and animal-based foods. The MIND diet, which is...read more
In the search for lifestyle strategies that slow cognitive decline associated with aging, medical researchers have been investigating the protective effects that certain dietary regimens could have on the brain. A study published in the journal Alzheimer’s & Dementia...read more
A study published in the Journal of Alzheimer’s Disease found that elderly adults who burned off more calories each week through physical exercise saw an increase in brain volume and a subsequent lower risk for Alzheimer’s disease. Although many studies have shown...read more
A form of gene therapy has yielded positive findings in the search for a potential cure to Alzheimer’s disease, according to research published from the journal Proceedings of the National Academy of Sciences. Researchers in the United Kingdom from Imperial College...read more
The risk factors for Alzheimer's disease are non-modifiable, physiological, and behavioral. Non-modifiable risk factors include age, which is the most prominent risk factor for Alzheimer’s disease. At 65 years of age, our chances of getting Alzheimer’s disease is...read more